




Sustainability Infosheet 2022

# Partnerships & scientific collaborations



idorsia



---

### Strategic partnerships: management approach

Our purpose is to discover, develop and commercialize innovative medicines to help more patients. We specialize in innovative small molecules and want to transform the horizon of therapeutic options. We cannot do this alone, so in order to promote innovation, enhance productivity and accelerate delivery of new medicines, we engage in mutually beneficial strategic partnerships. By partnering, we are able to reach our full potential, improve the lives of patients in need of our therapies and have a greater positive impact for all stakeholders.

Strategic partnerships – including collaborative research and development, and commercialization agreements – are a way of fully exploiting our discovery engine and clinical pipeline. We seek suitable external project partners to maximize the value of internal innovation.

Several of our strategic partnerships involve milestone payments based on the progress of the development compound in question, and/or revenue-sharing agreements, under which we are eligible to receive royalty

payments as a proportion of net sales. Our partnership with Actelion Pharmaceuticals (one of the Janssen Pharmaceutical Companies of Johnson & Johnson) is an example of a revenue sharing agreement, whereby Idorsia receives royalties for PONVORY® (ponesimod), a treatment approved by the FDA and EMA for relapsing forms of multiple sclerosis.

We have also entered into partnerships to gain access to technologies or services that are not part of our company's core capabilities, such as our agreement with Syneos Health to build the US and EUCAN sales force to support the launch of QUVIVIQ™.

Our strategic partnerships are overseen by the Chief Financial Officer in collaboration with the appropriate executive member of the internal research, development or commercial organization leading the partnership.

More information on our current strategic partnerships can be found [here](#).




# Other partnerships

We are also committed to the free exchange of ideas and information with the aim of advancing scientific discovery. To this end, we partner with organizations involved in similar areas of research and development so as to foster best practice sharing and cultivate an environment of innovation both inside and outside Idorsia.



# About this report



## Company profile

Headquartered in Allschwil, Switzerland – a European biotech hub – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options. The company has an experienced team of over 1,300 highly qualified professionals covering all disciplines from bench to bedside, and commercial operations in Europe, Japan, and the US – the ideal constellation for bringing innovative medicines to patients.

We are committed to achieving our ambitious goals in an economically, socially and environmentally responsible manner, and, as the company grows, our commitment to sustainability remains as important as ever.

We have a diversified and balanced clinical development pipeline covering multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases. Two Idorsia products are commercially available – QUVIVIQ™ (daridorexant) in the US and Europe, and PIVLAZ® (clazosentan) in Japan.

Idorsia Ltd is the Group's holding and finance company, with 14 subsidiaries across Europe, Asia and the US. Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017.

## About our sustainability reporting

The information contained in this info sheet covers the period from January 1, 2020 to December 31, 2022 and pertains to all significant locations of operation. In the context of its sustainability reporting, Idorsia considers significant locations of operation to be those with more than 20 permanent employees. Currently, this includes locations in Switzerland, the US and Japan. Any deviations from this reporting framework are indicated on a case-by-case basis.

The content of our sustainability reporting is aligned with the results of a materiality assessment and references the internationally recognized guidelines of the **Global Reporting Initiative (GRI)**.

For the full set of ESG info sheets, visit **[www.idorsia.com/sustainability](http://www.idorsia.com/sustainability)**

idorsia